Skip to content

Comparison of two articaine-based local anesthetics available in Brazil for wisdom tooth removal

Randomized double-blind split-mouth clinical trial comparing two formulations of 4% articaine with 1:100,000 epinephrine available in the Brazilian market for third molar extraction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-4nj2b8r
Enrollment
40
Registered
2026-07-20
Start date
2026-07-13
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Third molar Dentistry

Interventions

This is a randomized, controlled, two-arm, double-blind, split-mouth clinical trial. Experimental group: 40 surgical sites corresponding to impacted maxillary third molars will receive local anaesthes

Sponsors

Associação de Ensino Superior de Nova Iguaçu
Lead Sponsor
Associação de Ensino Superior de Nova Iguaçu
Collaborator

Eligibility

Age
18 Years to 30 Years

Inclusion criteria

Inclusion criteria: Male or female participants aged between 18 and 30 years; No known allergy to 4% articaine with 1:100,000 epinephrine; Body weight greater than 30 kg; In good general health at the time of enrolment and presence of an impacted distoangular maxillary third molar

Exclusion criteria

Exclusion criteria: Systemic diseases even if controlled; Neurological or psychiatric disorders; Regular use of anti-inflammatory drugs; History of photosensitivity; Acute pericoronitis; Advanced periodontal disease; Pregnant or breastfeeding women

Design outcomes

Primary

MeasureTime frame
To demonstrate that the new local anesthetic available on the Brazilian market does not cause pain during administration.

Secondary

MeasureTime frame
The study is expected to identify knowledge gaps, perceptions, and factors influencing dental students' clinical decision-making regarding the use of articaine, supporting improvements in evidence-based dental education.

Countries

BR

Contacts

Public ContactRodrigo Resende

Universidade Iguaçu

rresende@id.uff.br+55(21)997399282

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Aug 10, 2026